caa a22 4500 605490694 CHVBK 20210128100506.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10147-015-0843-2 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0843-2 Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia [Elektronische Daten] [Kazuhisa Hosoya, Sakiko Mochinaga, Akiko Emoto, Hiromi Yokoo, Hideaki Tokushima, Masayoshi Egoshi, Naoko Sueoka-Aragane, Shinya Kimura] Background: Poor adherence to ABL tyrosine kinase inhibitors (ABL TKIs) is associated with reduced treatment efficacy and increased healthcare costs. To examine the hazards associated with poor adherence, we implemented failure mode and effects analysis (FMEA). Methods: We surveyed 54 chronic myeloid leukemia (CML) patients treated at Saga University Hospital from October 2012 to May 2014. The survey consisted of items regarding the type of ABL TKI used, adherence to ABL TKIs, the appearance of adverse effects, utilisation of the high cost medical care benefit system, and factors affecting adherence. Four factors that likely affected adherence were identified, including the level of understanding of ABL TKIs treatment outcomes, adverse effects, the high cost of medications, and careless slips in the taking of medicine. Results of the survey were analysed by FMEA. Results: The risk priority number was highest for careless slips in the taking of medicine at 7.0±1.0 (mean±SEM), followed in descending order by the inadequate understanding of treatment outcomes (4.9±0.6), adverse effects (3.8±0.8), and high medication cost (2.2±0.5). Thus, the prevention of careless slips was the most important factor affecting adherence to ABL TKIs. Contrary to our preoccupation, FMEA revealed that high medication cost was the lowest risk factor for poor adherence. This finding may be attributed to the high utilisation (96.3%) of the high cost medical care benefit system. Conclusion: These findings suggest that an inadequate medication-taking habit such as careless slips may represent a potential target to improve and maximize adherence in CML patients. Japan Society of Clinical Oncology, 2015 Chronic myeloid leukemia nationallicence Failure mode and effects analysis nationallicence Adherence nationallicence ABL tyrosine kinase inhibitor nationallicence Hosoya Kazuhisa Department of Pharmacy, Saga University Hospital, Saga, Japan aut Mochinaga Sakiko Department of Pharmacy, Saga University Hospital, Saga, Japan aut Emoto Akiko Department of Pharmacy, Saga University Hospital, Saga, Japan aut Yokoo Hiromi Department of Pharmacy, Saga University Hospital, Saga, Japan aut Tokushima Hideaki Department of Pharmacy, Saga University Hospital, Saga, Japan aut Egoshi Masayoshi Department of Pharmacy, Saga University Hospital, Saga, Japan aut Sueoka-Aragane Naoko Department of Pharmacy, Saga University Hospital, Saga, Japan aut Kimura Shinya Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan aut International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1203-1210 1341-9625 20:6<1203 2015 20 10147 https://doi.org/10.1007/s10147-015-0843-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0843-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hosoya Kazuhisa Department of Pharmacy, Saga University Hospital, Saga, Japan aut NATIONALLICENCE 700 1- Mochinaga Sakiko Department of Pharmacy, Saga University Hospital, Saga, Japan aut NATIONALLICENCE 700 1- Emoto Akiko Department of Pharmacy, Saga University Hospital, Saga, Japan aut NATIONALLICENCE 700 1- Yokoo Hiromi Department of Pharmacy, Saga University Hospital, Saga, Japan aut NATIONALLICENCE 700 1- Tokushima Hideaki Department of Pharmacy, Saga University Hospital, Saga, Japan aut NATIONALLICENCE 700 1- Egoshi Masayoshi Department of Pharmacy, Saga University Hospital, Saga, Japan aut NATIONALLICENCE 700 1- Sueoka-Aragane Naoko Department of Pharmacy, Saga University Hospital, Saga, Japan aut NATIONALLICENCE 700 1- Kimura Shinya Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1203-1210 1341-9625 20:6<1203 2015 20 10147